Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118765
Recruitment Status : Completed
First Posted : April 18, 2017
Results First Posted : August 1, 2019
Last Update Posted : August 1, 2019
Sponsor:
Information provided by (Responsible Party):
Glenmark Specialty S.A.

Brief Summary:
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Condition or disease Intervention/treatment Phase
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) Drug: GSP304 (tiotropium bromide) Inhalation Solution Drug: GSP304 Placebo Inhalation Solution Drug: Spiriva® Respimat® inhalation spray Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 155 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Dose Ranging, Parallel Group, Active (Spiriva® Respimat®) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease
Actual Study Start Date : March 24, 2017
Actual Primary Completion Date : July 31, 2017
Actual Study Completion Date : July 31, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: Test Treatment T1: GSP304 Inhalation Solution Drug: GSP304 (tiotropium bromide) Inhalation Solution
Once daily (QD) oral inhalation using a nebulizer

Experimental: Test Treatment T2: GSP304 Inhalation Solution Drug: GSP304 (tiotropium bromide) Inhalation Solution
Once daily (QD) oral inhalation using a nebulizer

Experimental: Test Treatment T3: GSP304 Inhalation Solution Drug: GSP304 (tiotropium bromide) Inhalation Solution
Once daily (QD) oral inhalation using a nebulizer

Placebo Comparator: Test Treatment T4: GSP304 Placebo Inhalation Solution Drug: GSP304 Placebo Inhalation Solution
Once daily (QD) oral inhalation using a nebulizer

Active Comparator: Test Treatment T5: Spiriva® Respimat® inhalation spray Drug: Spiriva® Respimat® inhalation spray
Once daily (QD) oral inhalation




Primary Outcome Measures :
  1. Relative Bioavailability of Tiotropium With GSP304 in Comparison to SPIRIVA RESPIMAT 5 μg Based on CmaxSS [ Time Frame: Plasma concentrations on day 21 according to the below schedule: Pre-dose (0 hour), and at 2, 4, 6, 10, 15, 30, and 45, 60, 75, and 90 minutes post-dose, as well as 2, 4, 6, 8, 12, 16, 20 and 24 hours post-dose. ]
    The PK endpoint in plasma to assess the relative bioavailability was peak concentrations of tiotropium during the dosing interval at steady-state (CmaxSS)

  2. Relative Bioavailability of Tiotropium With GSP 304 in Comparison to SPIRIVA RESPIMAT 5 μg Based on AUC0-tauSS [ Time Frame: Plasma concentrations on day 21 according to the below schedule: Pre-dose (0 hour), and at 2, 4, 6, 10, 15, 30, and 45, 60, 75, and 90 minutes post-dose, as well as 2, 4, 6, 8, 12, 16, 20 and 24 hours post-dose. ]
    The PK endpoint in plasma to assess the relative bioavailability was area under the plasma concentration-time curve of tiotropium over the dosing interval at steady state (AUC0-tauSS)

  3. Change From Baseline (Day 1) in Trough FEV1 at 24 Hours After the Last Dose of Treatment on Day 21 in Comparison to Placebo. [ Time Frame: 21 days (Pre- dose trough FEV1 is mean FEV1 at -45 mins and -15 mins pre-morning dose at Day 1. Trough FEV1 is mean FEV1 obtained 23 hrs 15 mins and 23 hrs 45 mins post-morning dose of day 21). ]
    Change from baseline (Day 1) at Day 21 (Week 3) in trough FEV1 response at approximately 24 hours after the last dose (average of 23 hours 15 minutes and 23 hours 45 minutes postdose measurements), in comparison with placebo.


Secondary Outcome Measures :
  1. Amount (Aetau) (Cumulative Amount of Unchanged Drug Excreted Into the Urine Over the Dosing Interval) of Tiotropium Excreted in Urine Over the Dosing Interval on Day 1 [ Time Frame: Day 1 ]
    Descriptive statistics for tiotropium urine PK parameter - Amount (Aetau) of tiotropium excreted in urine over the dosing interval on Day 1

  2. Amount (Aetau) of Tiotropium Excreted in Urine Over the Dosing Interval on Day 21 [ Time Frame: Day 21 ]
    Descriptive statistics for tiotropium urine PK parameter - Amount (Aetau) of Tiotropium Excreted in Urine Over the Dosing Interval on Day 21

  3. Fraction of Dose (Fe) of Tiotropium Excreted in Urine Over the Dosing Interval on Day 1 [ Time Frame: Day 1 ]
    Descriptive statistics for tiotropium urine PK parameter - Fraction of dose (Fe) of tiotropium excreted in urine over the dosing interval on Day 1

  4. Fraction of Dose (Fe) of Tiotropium Excreted in Urine Over the Dosing Interval on Day 21 [ Time Frame: Day 21 ]
    Descriptive statistics for tiotropium urine PK parameter-Fraction of Dose (Fe) of Tiotropium Excreted in Urine Over the Dosing Interval on Day 21

  5. Peak Concentrations During the Dosing Interval (Cmax) on Day 1 [ Time Frame: Day 1 ]
    Descriptive statistics for tiotropium plasma PK parameters - (Cmax) on Day 1

  6. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC0-tau) on Day 1 [ Time Frame: Day 1 ]
    Descriptive statistics for tiotropium plasma PK parameter - Area under the plasma concentration-time curve over the dosing interval (AUC0-tau) on Day 1

  7. Time of Peak Drug Concentration Over the Dosing Interval (Tmax) on Day 1 [ Time Frame: Day 1 ]
    Descriptive statistics for tiotropium plasma PK parameter - Time of peak drug concentration over the dosing interval (tmax) on Day 1

  8. Time of Peak Drug Concentration Over the Dosing Interval (Tmax) on Day 21 [ Time Frame: Day 21 ]
    Descriptive statistics for tiotropium plasma PK parameter - Time of peak drug concentration over the dosing interval (tmax) on Day 21

  9. Average Concentration During a Dosing Interval at Steady State (CavSS) on Day 21 [ Time Frame: Day 21 ]
    Descriptive statistics for tiotropium plasma PK parameter - Average concentration during a dosing interval at steady state (CavSS) on day 21

  10. Accumulation Ratio Rac(Auc) [ Time Frame: Day 21 ]
    Descriptive statistics for tiotropium plasma PK parameter-Accumulation ratio Rac(auc). Rac(auc) was calculated as AUC0-tauSS/AUC0-tau.

  11. Accumulation Ratio Rac(Cmax) [ Time Frame: Day 21 ]
    Descriptive statistics for tiotropium plasma PK parameter-Accumulation ratio Rac(cmax). Rac(Cmax) was calculated as CmaxSS/Cmax.

  12. Change From Baseline in Peak FEV1 Within 12 Hours Post-dose on Day 1 [ Time Frame: Day 1 (Pre-dose FEV1 at -45 mins and 15 mins prior to dosing on Day 1. On Day 1 FEV1 at post-dose at 5 mins ±3, 15 mins ±2, 30 mins ±5, 60 mins, 90 mins, and 2 hours; and post-dose at 4, 6, 8, 10, 12 hours after the morning dose). ]
    The least square mean change from baseline to peak FEV1 within 12 hours postdose on Day 1. Change from baseline in peak FEV1 within 12 hours postdose on Day 1 was derived from the serial readings taken through 12 hours postdose and calculating the change from baseline.

  13. Change From Baseline in Peak FEV1 Within 12 Hours Post-dose on Day 21 [ Time Frame: Day 21(Pre-dose FEV1 at -45 mins and 15 mins prior to dosing on Day 21. On Day 21, FEV1 at post-dose at 5 mins ±3, 15 mins ±2, 30 mins ±5, 60 mins, 90 mins, and 2 hours; and post-dose at 4, 6, 8, 10, 12 hours after the morning dose). ]
    The least square mean change from baseline to peak FEV1 within 12 hours postdose on Day 21. Change from baseline in peak FEV1 within 12 hours postdose on Day 21 was derived from the serial readings taken through 12 hours postdose and calculating the change from baseline.

  14. Change From Baseline in Forced Vital Capacity (FVC) on Day 1 [ Time Frame: Day 1 (Pre-dose FVC at -45 mins and 15 mins prior to dosing on Day 1. Postdose timing were relative to the end of dosing.The window for 1 hour spirometry and thereafter was ±5 minutes). ]
    Least Square Mean change from baseline in forced vital capacity (FVC) to end of Day 1.

  15. Change From Baseline in Forced Vital Capacity (FVC) on Day 21 [ Time Frame: Day 21 (Pre-dose FVC at -45 mins and 15 mins prior to dosing on Day 21. Postdose timing were relative to the end of dosing. The window for 1 hour spirometry and thereafter was ±5 minutes). ]
    Least Square Mean change from baseline in forced vital capacity (FVC) to end of Day 21

  16. Change From Baseline in Time-normalized Area Under the Curve for FEV1 Measured Over 12 Hours on Day 1 [ Time Frame: Day 1 (Pre-dose FEV1 at -45 mins and 15 mins prior to dosing on Day 1. On Day 1 FEV1 at post-dose at 5 mins ±3, 15 mins ±2, 30 mins ±5, 60 mins, 90 mins, and 2 hours; and post-dose at 4, 6, 8, 10, 12 hours after the morning dose). ]
    Least Square Mean (SE) change from baseline in time-normalized area under the curve for FEV1 measured over 12 hours on Day 1.

  17. Change From Baseline in Time-normalized Area Under the Curve for FEV1 Measured Over 12 Hours on Day 21 [ Time Frame: Day 21(Pre-dose FEV1 at -45 mins and 15 mins prior to dosing on Day 21. On Day 21, FEV1 at post-dose at 5 mins ±3, 15 mins ±2, 30 mins ±5, 60 mins, 90 mins, and 2 hours; and post-dose at 4, 6, 8, 10, 12 hours after the morning dose). ]
    Least Square Mean (SE) change from baseline in time-normalized area under the curve for FEV1 Measured Over 12 Hours on Day 21.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects ≥40 years and ≤85 years of age at the time of consent.
  • Subject must have a primary diagnosis of mild or moderate COPD defined as post-bronchodilator FEV1/FVC ratio of <70% and FEV1 of ≥50% of predicted normal value as per the NHANES III predicted normal values at screening.
  • Willing to stop all other COPD medications or other medications which will interfere with the study results for the entire duration of the study, except albuterol/salbutamol as needed.
  • Current or ex-smoker with ≥10 pack-year smoking history.

Exclusion Criteria:

  • Subjects with a chest x-ray/CT scan that suggests a diagnosis other than COPD (eg, pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions) and taken within 6 months prior to study start. If there is no chest x-ray or CT scan taken within 6 months prior to study start, or if recent results are unavailable for review, a chest x-ray must be performed.
  • Use of oral/parenteral corticosteroids or antibiotics for COPD within 6 weeks or depot corticosteroids within 3 months prior to screening or subject has had a change in dose or type of any medications for COPD within 14 days before screening.
  • Hospitalization for COPD exacerbation or pneumonia within 3 months prior to screening.
  • Subjects with a history of asthma, with the exception of outgrown childhood asthma, defined as transient wheezers outgrown by 5 years of age.
  • Subject has a known history of alpha 1 antitrypsin deficiency-related emphysema.
  • Subject requires nocturnal oxygen or continuous supplemental oxygen therapy.
  • Subject with history of a positive result for HBsAg or HCV antibody.
  • Subject is known to be seropositive for human immunodeficiency virus.
  • Female subject is pregnant or lactating.
  • Subject has a history of allergic reaction to the anti-cholinergic or any components of the study medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118765


Locations
Show Show 25 study locations
Sponsors and Collaborators
Glenmark Specialty S.A.
Investigators
Layout table for investigator information
Study Director: Cynthia Caracta, MD FCCP Glenmark Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Glenmark Specialty S.A.:
Statistical Analysis Plan  [PDF] September 12, 2017
Study Protocol  [PDF] April 13, 2017

Layout table for additonal information
Responsible Party: Glenmark Specialty S.A.
ClinicalTrials.gov Identifier: NCT03118765    
Other Study ID Numbers: GSP304-201
First Posted: April 18, 2017    Key Record Dates
Results First Posted: August 1, 2019
Last Update Posted: August 1, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bromides
Tiotropium Bromide
Pharmaceutical Solutions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anticonvulsants